Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Low Tidal Volume Strategy In Cardiogenic Pulmonary Edema: The Logical Trial (LOGICAL)

Some people with heart failure develop fluid buildup in the lungs and need a breathing machine while they are treated in an intensive care unit. The amount of air delivered with each breath may affect how quickly they recover.

The LOGICAL study will compare two ways of setting the breathing machine: delivering a lower or an intermediate amount of air with each breath. About 300 adults in intensive care units across Spain will be randomly assigned to one of these strategies.

The study aims to find out whether the lower amount of air increases the number of days patients are alive and breathing without the machine during the first 28 days after assignment. The researchers will also assess other outcomes, including survival and length of stay in the intensive care unit and hospital.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

300

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Admission to a participating intensive care unit (ICU).

  2. Within the first 24 hours of invasive mechanical ventilation, whether ventilation was started before or after admission to the participating ICU.

  3. Expected duration of invasive mechanical ventilation greater than 24 hours.

  4. Acute hypoxemic respiratory failure of cardiogenic origin, meeting all three of the following criteria:

    1. PaO2/FiO2 ratio below 300 mmHg.

    2. Pulmonary congestion shown by at least one of the following:

      • Lung ultrasound showing multiple B-lines (at least 3 per zone), distributed bilaterally in at least 2 zones per hemithorax; or
      • Chest radiograph showing interstitial or alveolar edema, vascular redistribution, or Kerley B-lines.
    3. Evidence of a cardiogenic origin shown by at least one of the following:

      • Echocardiographic evidence of elevated left-sided filling pressures (E/e' >14 or E/A >2); or
      • Pulmonary capillary wedge pressure >15 mmHg measured with a pulmonary artery catheter.

Exclusion Criteria:

  1. Participation in another interventional clinical trial.
  2. More than 24 hours of invasive mechanical ventilation.
  3. Extracorporeal support already initiated.
  4. Expected extubation within the next 24 hours.
  5. A predominantly noncardiogenic cause of acute respiratory failure, including acute respiratory distress syndrome, active pneumonia or other pulmonary infection, confirmed pulmonary embolism, or acute lung injury of noncardiac origin.
  6. Pregnancy.
  7. Risk of or suspected elevated intracranial pressure.
  8. Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV chronic obstructive pulmonary disease.
  9. Known pre-existing interstitial lung disease.
  10. Previous pneumonectomy or lobectomy.
  11. Terminal condition, a decision to limit life-sustaining treatment, or a do-not-resuscitate order.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Low Tidal Volume Ventilation

Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 ml/kg of predicted body weight. Tidal volume may be reduced to 4 ml/kg according to respiratory mechanics and clinical tolerance.

Volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 mL/kg of predicted body weight. Tidal volume may be reduced stepwise to 4 mL/kg according to respiratory mechanics and clinical tolerance.

Aktiv komparator: Intermediate Tidal Volume Ventilation

Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining airway pressures within the protocol-defined safety limits.

Volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining plateau pressure below 30 cmH₂O and driving pressure below 15 cmH₂O.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Days Alive and Free of Invasive Mechanical Ventilation Through Day 28
Tidsramme: From randomization through day 28

Number of days from randomization through day 28 that a participant is alive and free of invasive mechanical ventilation. Participants who die before day 28 are assigned 0 days. Higher values indicate a more favorable outcome.

From randomization through day 28

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
All-Cause Mortality at Day 28
Tidsramme: From randomization through day 28

Percentage of participants who die from any cause within 28 days after randomization.

From randomization through day 28
Duration of Invasive Mechanical Ventilation
Tidsramme: From randomization until successful liberation, death, or day 90

Time from randomization to successful liberation from invasive mechanical ventilation, defined as remaining free of invasive mechanical ventilation for at least 48 hours. Death before liberation will be considered a competing event in the analysis.

From randomization until successful liberation, death, or day 90

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Laura Amado-Rodríguez, MD, PhD, Hospital Universitario Central de Asturias

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. august 2028

Studieafslutning (Anslået)

1. oktober 2028

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • LOGICAL Trial

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

The investigators intend to explore sharing anonymized individual participant data after publication of the main results, subject to ethical approval, applicable data protection requirements, and assessment of re-identification risk. The specific data sets, access process, and availability period have not yet been determined.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner